Prof. Yubao Zhang 张玉宝
Chief Physician, Professor
Department of Hepatobiliary and Pancreatic Surgery, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and surgical treatment of hepatobiliary and pancreatic tumors, with a specific focus on the diagnosis and treatment of obstructive jaundice.
Dr. Zhang is Chief Physician and Professor in Hepatobiliary and Pancreatic Surgery at Harbin Medical University Cancer Hospital. With over 20 years in abdominal tumor surgery, Dr. Zhang holds an MD from Harbin Medical University and was a visiting scholar at Nippon Medical School in Japan. Additional training included fellowships at Shanghai Changhai Hospital and Eastern Hepatobiliary Surgery Hospital. Dr. Zhang has authored medical audiovisual textbooks on gastric and pancreatic head cancer surgeries.
Professional roles
- Member, Gastric Cancer Professional Committee, Heilongjiang Anti-Cancer Association
- Member, Expert Pool for Medical Malpractice Technical Appraisal, Harbin Medical Association
- Member, Geriatric Oncology Professional Committee, Heilongjiang Geriatrics Association
- Member, Liver Cancer Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhang Yubao). Papers usually list the name as Yubao Zhang or Zhang Y.
Selected publications
18 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- iScience, 2026 (senior author): STRAP promotes hepatocellular carcinoma progression through activation of an STRAP/Wnt-β-catenin/STRAP positive feedback loop. PubMed 42338478
- Discov Oncol, 2025 (senior author): Multi-omics integration of TPX2 in prognostic prediction in resectable hepatocellular carcinoma. PubMed 40506577
- BMC Bioinformatics, 2023 (senior author): Pan-cancer analysis of SYNGR2 with a focus on clinical implications and immune landscape in liver hepatocellular carcinoma. PubMed 37170221
- Biosci Rep, 2019 (senior author): LncRNA XIST enhanced TGF-β2 expression by targeting miR-141-3p to promote pancreatic cancer cells invasion. PubMed 31213574
- Exp Ther Med, 2016 (senior author): Palliation double stenting for malignant biliary and duodenal obstruction. PubMed 26889267
- Biochem Biophys Res Commun, 2015 (senior author): miR-342-3p affects hepatocellular carcinoma cell proliferation via regulating NF-κB pathway. PubMed 25580008
- PLoS One, 2014 (senior author): MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α. PubMed 25531114
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion